Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
AXON Axovant Sciences Ltd. daily Stock Chart
AXON [NASD]
Axovant Sciences Ltd.
Healthcare | Biotechnology | United Kingdom
financial highlights | statements
Index- P/E- EPS (ttm)-2.36 Insider Own0.10% Shs Outstand114.12M Perf Week-8.37%
Market Cap131.24M Forward P/E- EPS next Y-1.50 Insider Trans0.00% Shs Float31.97M Perf Month-22.30%
Income-249.10M PEG- EPS next Q-0.40 Inst Own25.00% Short Float7.60% Perf Quarter-44.44%
Sales- P/S- EPS this Y-29.50% Inst Trans0.25% Short Ratio2.58 Perf Half Y-81.36%
Book/sh0.99 P/B1.16 EPS next Y32.70% ROA-102.30% Target Price11.14 Perf Year-94.59%
Cash/sh1.65 P/C0.70 EPS next 5Y- ROE-168.60% 52W Range1.14 - 27.98 Perf YTD-78.18%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-95.99% Beta-
Dividend %- Quick Ratio4.60 Sales past 5Y- Gross Margin- 52W Low-1.68% ATR0.09
Employees69 Current Ratio4.60 Sales Q/Q- Oper. Margin- RSI (14)32.28 Volatility5.62% 6.84%
OptionableYes Debt/Eq0.49 EPS Q/Q-11.50% Profit Margin- Rel Volume0.56 Prev Close1.15
ShortableYes LT Debt/Eq0.45 EarningsApr 24 AMC Payout- Avg Volume941.18K Price1.12
Recom2.70 SMA20-11.68% SMA50-24.18% SMA200-87.68% Volume298,428 Change-2.54%
Jan-10-18Upgrade Chardan Capital Markets Sell → Neutral $2.50
Dec-21-17Downgrade Jefferies Buy → Hold
Sep-27-17Downgrade Robert W. Baird Outperform → Neutral $29 → $6
Sep-26-17Reiterated Chardan Capital Markets Sell $8 → $3
Sep-26-17Downgrade Piper Jaffray Overweight → Neutral
Sep-08-17Resumed Evercore ISI Outperform $30
Jul-11-17Initiated Jefferies Buy
Jun-14-17Reiterated Oppenheimer Outperform $26 → $30
Dec-20-16Initiated Laidlaw Sell $7.50
Dec-07-16Initiated Oppenheimer Outperform $20
Jun-07-16Initiated Leerink Partners Outperform $22
Jan-08-16Initiated H.C. Wainwright Buy $35
Oct-22-15Initiated Piper Jaffray Overweight
Sep-25-15Reiterated Chardan Capital Markets Sell $9.50 → $8
Jul-15-15Initiated JMP Securities Mkt Outperform $36
Jul-13-15Initiated Robert W. Baird Outperform $29
Jul-06-15Initiated RBC Capital Mkts Outperform $40
Jul-06-15Initiated Jefferies Buy $31
Jun-18-15Initiated Chardan Capital Markets Sell $10
Mar-22-18 03:25PM  Pair Trade Closed: Chardan No Longer Advocates Owning vTv Therapeutics Over Axovant Benzinga
Feb-15-18 08:30AM  Options Traders Expect Huge Moves in Axovant Sciences (AXON) Stock Zacks
Feb-14-18 09:00AM  AXON INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Axovant Sciences Ltd. Investors Business Wire -9.94%
Feb-13-18 12:41AM  [$$] Axovant Stock Tumbles After Sweeping Leadership Changes The Wall Street Journal +17.92%
Feb-12-18 02:57PM  Axovant shares slide 21% premarket on news of CEO, COO departures MarketWatch -19.63%
01:54PM  [$$] Axovant Stock Tumbles After Sweeping Leadership Changes The Wall Street Journal
11:10AM  Axovant Sciences CEO David Hung resigns, shares tumble Reuters
10:18AM  Axovant Shares Crater as CEO and President Both Resign TheStreet.com
07:00AM  Axovant Sciences Announces Changes to Management Team and Board of Directors GlobeNewswire
Jan-17-18 06:10AM  Five Rules for This Market Beast: Cramer's 'Mad Money' Recap (Tues 1/16/18) TheStreet.com
Jan-10-18 11:45AM  After A Freefall In Axovant Shares, Chardan Upgrades Benzinga
08:46AM  Implied Volatility Surging for Axovant Sciences (AXON) Stock Options Zacks
07:23AM  Biotech Stock Roundup: Celgene to Acquire Impact, J.P. Morgan Healthcare Conference in Focus Zacks
Jan-09-18 08:05AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
07:00AM  CORRECTION: Axovant Announces Negative Results for Intepirdine in Phase 2b HEADWAY and Pilot Phase 2 Gait and Balance Studies; Positive Trends in Efficacy Seen in Pilot Phase 2 Nelotanserin Study GlobeNewswire
12:57AM  Despite Setbacks, Drugmakers Have Plans to Fight Alzheimers The Wall Street Journal
Jan-08-18 07:27PM  Drug Industry Isn't Giving Up on Alzheimer's The Wall Street Journal -56.98%
04:32PM  Why Dave & Buster's Entertainment, Axovant Sciences, and Five Below Slumped Today Motley Fool
12:35PM  Roivant-backed company partners with DCRI American City Business Journals
12:21PM  Here's Why Axovant Sciences Dropped Today Motley Fool
11:48AM  [$$] Axovant Will No Longer Develop Lead Dementia Drug The Wall Street Journal
10:10AM  Axovant Crumbles Following Alzheimers Study Update 24/7 Wall St.
10:03AM  Axovant shares plunge after key dementia drug programme scrapped Reuters
08:00AM  Axovant's stock tumbles toward record low after disappointing drug trial results MarketWatch
07:25AM  Axovant to scrap intepirdine program after dementia trial fails Reuters
07:00AM  Axovant Announces Negative Results for Intepirdine in Phase 2b HEADWAY and Pilot Phase 2 Gait and Balance Studies; Positive Trends in Efficacy Seen in Pilot Phase 2 Nelotanserin Study GlobeNewswire
Jan-05-18 07:00AM  Axovant to Present at 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-02-18 08:05AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
Dec-19-17 08:53AM  Are Options Traders Betting on a Big Move in Axovant Sciences (AXON) Stock? Zacks
Dec-18-17 08:08AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
Dec-15-17 08:08AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
Dec-08-17 08:03AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit +5.58%
Nov-30-17 08:05AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
Nov-22-17 08:06AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
Nov-20-17 08:07AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit +7.82%
Nov-17-17 08:06AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
Nov-16-17 08:04AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
Nov-15-17 08:05AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
Nov-06-17 11:22AM  Is Axovant Sciences Ltds (AXON) Balance Sheet A Threat To Its Future? Simply Wall St.
Nov-02-17 04:30PM  Axovant Announces Second Fiscal Quarter Financial Results and Corporate Updates GlobeNewswire
Oct-27-17 08:39AM  Alkermes (ALKS) in Focus: Stock Moves 11.1% Higher Zacks
Oct-25-17 08:04AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
Oct-24-17 08:03AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
07:30AM  [$$] Alector Nabs $205 Million in Development Deal With AbbVie The Wall Street Journal
Oct-20-17 08:04AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
Oct-18-17 08:42AM  Abeona Therapeutics (ABEO) Surges: Stock Moves 7.2% Higher Zacks -6.07%
08:32AM  Protalix BioTherapeutics (PLX) Jumps: Stock Rises 9% Zacks
Oct-17-17 08:39AM  uniQure (QURE) in Focus: Stock Moves 11.9% Higher Zacks
Oct-16-17 08:04AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
Oct-11-17 08:37AM  Rexahn Pharmaceuticals (RNN) in Focus: Stock Moves 6.1% Higher Zacks
Oct-10-17 08:04AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
Oct-06-17 08:04AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit -10.98%
Oct-03-17 01:41PM  Roivant Wins A Battle Forbes
11:25AM  Biotech Can Keep Rallying Through The End Of The Year Barrons.com
09:53AM  After Intepirdine Flunked in Alzheimers Disease, Is Axovant Sciences a Buy? Motley Fool
Sep-30-17 12:31AM  [$$] How a Failed Alzheimers Drug Stung Some Large Hedge Funds The Wall Street Journal
Sep-29-17 05:05PM  [$$] How a Failed Alzheimer's Drug Stung Some Large Hedge Funds The Wall Street Journal
08:03AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
Sep-28-17 12:58PM  Here Is What Vivek Ramaswamy Wrote To His Employees After Axovant's Drug Failed Forbes
Sep-27-17 04:33PM  Snapback Rally Sends Axovant Sciences 10% Higher Today Motley Fool +10.43%
09:49AM  Company News For Sep 27, 2017 Zacks
09:46AM  Axovant Rises After Tuesday's Plunge - Biotech Movers TheStreet.com
08:20AM  Today's Research Reports on Stocks to Watch: Axovant and Moleculin ACCESSWIRE
12:39AM  [$$] Why Biotechs Retreat Wont Be as Dramatic This Time The Wall Street Journal
12:38AM  [$$] Axovant Says Experimental Drug Failed Trials in Treating Alzheimers Disease The Wall Street Journal
Sep-26-17 06:00PM  Axovant Sciences' Alzheimer's Disease Trial Comes Up Empty -- What Now? Motley Fool -73.90%
04:30PM  Why Axovant Sciences, The Habit Restaurants, and Silvercorp Metals Slumped Today Motley Fool
04:26PM  Axovant Shares Plummet On Alzheimer's Data; Genocea Gets Rocked -Biotech Movers TheStreet.com
04:22PM  This Biotech Craters 70% On Late-Stage Alzheimer's Drug Failure Investor's Business Daily
04:04PM  Axovant, Genocea Plunge into Tuesdays 52-Week Low Club 24/7 Wall St.
03:00PM  Biotech's Boy Wonder Calls Alzheimer's Drug His 'Single Greatest Failure' Forbes
01:27PM  Axovant Sciences (AXON) Stock Crashed Over 70%: Here's Why Zacks
12:50PM  Axovant Alzheimer's drug fails late-stage trial CNBC Videos
12:35PM  Roivant subsidiary sees stock tumble on negative Alzheimers results American City Business Journals
12:24PM  Is Axovant Sciences Stock a Bad-News Buy? Motley Fool
10:01AM  [$$] Why Biotech's Retreat Won't Be as Dramatic This Time The Wall Street Journal
08:55AM  Axovant's stock is crashing after failing a key drug trial Business Insider
08:50AM  Why Axovant Is Getting Absolutely Crushed 24/7 Wall St.
08:03AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
07:59AM  [$$] Axovant Alzheimer's drug fails in clinical trials Financial Times
07:32AM  UPDATE: Axovant shares tumble 71% after late-stage trial of Alzheimer's treatment fails to meet primary goals MarketWatch
07:18AM  A biotech founded by a 32-year-old just failed a key Alzheimer's drug trial Business Insider
07:10AM  Axovant's Alzheimer's drug fails late-stage trial Reuters
07:00AM  Axovant Announces Negative Topline Results of Intepirdine Phase 3 MINDSET Trial in Alzheimer's Disease PR Newswire
Sep-25-17 05:00AM  Alzheimers Drug May Mean $2 Billion Opportunity for Axovant Bloomberg
Sep-22-17 01:16PM  Traders expect an 80% move for this hot biotech stock in the next month CNBC
08:40AM  Options Traders Expect Huge Moves in Axovant Sciences (AXON) Stock Zacks
Sep-21-17 05:31PM  3 Biotech Stocks With Major Catalysts Incoming Motley Fool
07:55AM  Venturing Boldly Into Neuroscience Forbes
Sep-19-17 08:35AM  Axovant Sciences Ltd. (AXON) Jumps: Stock Rises 7.2% Zacks +6.08%
03:00AM  Axovant Sciences Shows Rising Price Performance With Jump To 93 RS Rating Investor's Business Daily
Sep-12-17 08:02AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit -7.74%
03:00AM  Axovant Sciences Joins Elite Club Of Stocks With RS Ratings Over 90 Investor's Business Daily
Sep-11-17 08:40AM  Are Options Traders Betting on a Big Move in Axovant Sciences (AXON) Stock? Zacks +5.47%
Sep-06-17 01:35PM  Why September Will Be A 'Make Or Break' Month For These Biotechs Investor's Business Daily
09:23AM  Today's Bell Ringer, September 6, 2017 CNBC Videos
07:00AM  Axovant to Present at Two Upcoming Investor Conferences PR Newswire
Aug-30-17 10:56AM  QVT Financials Investments, Performance, Letters Insider Monkey
07:40AM  Featured Company News - AVEO Pharma's FOTIVDA(R) Licensed in EU for the Treatment of Advanced Renal Cell Carcinoma ACCESSWIRE
Aug-22-17 08:05AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for the treatment of dementia and related neurological disorders in the United States and Europe. Its lead product candidate, intepirdine, a selective 5-HT6 receptor antagonist, which is in Phase III clinical trial for the treatment of Alzheimer's disease; in Phase IIb clinical trial for treating dementia with Lewy bodies (DLB); and in Phase II clinical trial for treating cait and balance in Alzheimer's disease, DLB, and Parkinson's disease dementia. The company is also developing nelotanserin, a selective 5-HT2A receptor inverse agonist, which is in Phase II clinical trial for the treatment of visual hallucinations in patients with Lewy body dementia (LBD) and REM behavior disorder in patients with LBD. In addition, it focuses on developing RVT-103, a combination of donepezil and a peripheral muscarinic receptor antagonist; and RVT-104, a combination of rivastigmine and a peripheral muscarinic receptor antagonist as treatments for patients with Alzheimer's disease or DLB. The company was formerly known as Roivant Neurosciences Ltd. and changed its name to Axovant Sciences Ltd. in March 2015. The company was founded in 2014 and is based in London, the United Kingdom. Axovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Modig BerndtDirectorDec 29Option Exercise0.9077,91470,12377,914Jan 03 08:39 AM
open in yahoo | open in reuters | open in google